Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression - Real-World Data from the German Cutaneous Lymphoma Network

Q: What patient group was evaluated in this study?

The study evaluated 32 patients with advanced-stage mycosis fungoides or Sézary syndrome and low CD30 expression (<10%).

Q: How was BV administered and how was response measured?

All patients received BV at standard dose, and treatment response was assessed using EORTC-ISCL criteria.

Q: What were the key efficacy outcomes reported for BV?

The overall response rate was 53.1%, with complete responses 12.5% and partial responses 40.6%. Median progression-free survival was 4.0 months and median time to next treatment was 7.25 months.

Sep 30, 2026

Uploaded by Logic

Advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) are aggressive cutaneous T-cell lymphomas with limited treatment options and poor prognosis. Brentuximab vedotin (BV) is active in tumors with CD30 expression ≥10%, but real-world evidence for low CD30 expression (<10%) is scarce. A retrospective multicenter analysis evaluated BV efficacy in 32 advanced MF/SS patients across German CTCL centers. Overall response rate was 53.1% with median PFS 4.0 months and median TTNT 7.25 months.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Simple Summary

Abstract

Background/Objectives

Methods

Results

Conclusions

Article Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network Christoph Blazejak 1,†, Mathias Oymanns 1,†, René Stranzenbach 2,3, Uwe Hillen 4,5, Christina Mitteldorf 6, Jan P. Nicolay 7, Marion Wobser 8, Philipp Schrüfer 8,9, Janika Gosmann 10, Ulrike Wehkamp 11,12,13, Nina Booken 14, Alexander Kreuter 15, Edgar Dippel 16, Claus-Detlev Klemke 17, Maria Weyermann 18, Rudolf Stadler 10 and Chalid Assaf 1,19,20, * Academic Editor: Daruka Mahadevan Received: 27 November 2025 Revised: 21 December 2025 Accepted: 25 December 2025 Published: 28 December 2025 Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. 1 Department of Dermatology, Helios Klinikum Krefeld, Health and Medical University Düsseldorf-Krefeld, 47805 Krefeld, Germany 2 Department of Dermatology, Universitätsklinikum Bochum, 44801 Bochum, Germany 3 Dermatology Practice Dr. R. Stranzenbach, 58285 Gevelsberg, Germany 4 Department of Dermatology, Vivantes Klinikum Neukölln, 12351 Berlin, Germany 5 MVZ Dermatopathologie Duisburg Essen GmbH, 45147 Essen, Germany 6 Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, 37075 Göttingen, Germany 7 Department of Dermatology, University Medical Center Mannheim, 68167 Mannheim, Germany; [jan.nicolay@umm.de](jan.nicolay@umm.de) 8 Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, 97080 Würzburg, Germany; philipp.schruefer@hin.ch (P.S.) 9 Skinmed AG, 5600 Lenzburg, Switzerland 10 Department of Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Clinic, University Hospital of the Ruhr University Bochum, 32429 Minden, Germany; janika.gosmann@unimedizin-ffm.de (J.G.) 11 Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, 24105 Kiel, Germany 12 Medical School Hamburg, University of Applied Sciences and Medical University, 20457 Hamburg, Germany 13 Helios Kliniken GmbH, 10117 Berlin, Germany 14 Department of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany 15 Department of Dermatology, Helios Klinikum Oberhausen, Universität Witten/Herdecke, 46045 Oberhausen, Germany 16 Department of Dermatology and Venereology, Klinikum Ludwigshafen, 67063 Ludwigshafen, Germany 17 Department of Dermatology and Skin Tumor Center, Municipal Hospital Karlsruhe, Academic Teaching Hospital of the University of Freiburg, 76133 Karlsruhe, Germany 18 Department of Health Care, Niederrhein University of Applied Sciences, 47805 Krefeld, Germany; maria.weyermann@hs-niederrhein.de 19 Institute for Molecular Medicine, Medical School Hamburg, University of Applied Sciences and Medical University, 20457 Hamburg, Germany 20 Faculty of Medicine, Health and Medical University Düsseldorf-Krefeld, 47805 Krefeld, Germany * Correspondence: [chalid.assaf@helios-gesundheit.de](chalid.assaf@helios-gesundheit.de)[ ](chalid.assaf@helios-gesundheit.de)† These authors contributed equally to this work. Simple Summary Advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) are aggressive cutaneous T-cell lymphomas with limited treatment options and poor prognosis. Brentuximabvedotin (BV), an anti-CD30 antibody–drug conjugate, has shown high efficacy in patients with CD30 expression ≥ 10%, but data in low-CD30-expressing tumors are limited. This retrospective multicenter study evaluated 32 patients with advanced MF/SS and CD30 expression < 10% treated with standard-dose BV. All patients had received prior systemic therapies (median: 3) . The overall response rate (ORR) was 53.1%, including 12.5% complete and 40.6% partial responses. Median progression-free survival (PFS) was 4.0 months,

FAQs

What patient group was evaluated in this study?

The study evaluated 32 patients with advanced-stage mycosis fungoides or Sézary syndrome and low CD30 expression (<10%).

How was BV administered and how was response measured?

All patients received BV at standard dose, and treatment response was assessed using EORTC-ISCL criteria.

What were the key efficacy outcomes reported for BV?

The overall response rate was 53.1%, with complete responses 12.5% and partial responses 40.6%. Median progression-free survival was 4.0 months and median time to next treatment was 7.25 months.

Sep 30, 2026

Uploaded by Logic